The above images are the property of and under license by the Waikato District Health Board.
For illustrative purposes only. Models are not clinical trial patients. Example severity strata based on literature.
Example representation of IGA scoring. Not an actual patient.
Advise the patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Instruct patients or caregivers:
to perform the first self-injection under the supervision and guidance of a qualified healthcare provider for proper training in subcutaneous injection technique
to inject the full dose of Adbry
to follow sharps disposal recommendations
Advise patients to discontinue Adbry and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions
Advise patients to consult their healthcare provider if new-onset or worsening eye symptoms develop
Advise patients that Adbry may increase the risk of infection following administration of live vaccines and that vaccination with live vaccines is not recommended during Adbry treatment. Instruct patients to inform the healthcare provider that they are taking Adbry prior to a potential vaccination
References: 1. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI) assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-18. 2. Lesham YA, Hajar T, Hanifin JM, et al. What the eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015; 172(5):1353-1357.
ADBRY™ (tralokinumab-ldrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
Please see Full Prescribing Information.
